Hepatitis C Support Group
Hepatitis C is a blood-borne viral disease which can cause liver inflammation, fibrosis, cirrhosis and liver cancer. The hepatitis C virus (HCV) is spread by blood-to-blood contact with an infected person's blood. Many people with HCV infection have no symptoms and are unaware of the need to seek treatment. Hepatitis C infects an estimated 150-200 million people worldwide.
Get another opinion! She probably hasent checked it out.
You are correct Ecc not all will do the interfuron. It is a love hate for me right now!
Praying for you all!
Every fall, hepatitis and liver disease experts gather to share the latest viral hepatitis research and treatment updates at the Liver MeetingTM . I had the opportunity to attend this years meeting, held last month in Boston. The meeting was particularly exciting because it featured new information about many novel hepatitis C treatments currently in development as well as the latest updates about how to best use currently available treatments.
There were numerous conversations about the new standard of care for hepatitis C: triple therapy that involves combining one of two recently approved oral agents with traditional medications (pegylated interferon and ribavirin). Studies shared at the meeting indicated that this triple therapy is offering patients better outcomesit can cure up to 80 percent of people who complete the treatmentsometimes with shorter therapy than the former standard treatment. The new triple therapy lasts only six to twelve months. However, there was also discussion of the side effects that can complicate or cause some patients to defer or stop treatment prematurely. The race is on to find better treatments that have fewer side effects, work faster, andmost importantlycure more patients with chronic hepatitis C. According to information shared at the meeting, there are over 30 new hepatitis C drugs in development and there is optimism that some of these new drugs may be able to achieve cure rates approaching 100 percent.. The second generation of new oral drugs is expected to become available within the next two years and even more effective combinations are expected within 5-7 years.